Voya Investment Management LLC Sells 25,239 Shares of Axsome Therapeutics, Inc. $AXSM

by · The Markets Daily

Voya Investment Management LLC lowered its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 18.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 114,050 shares of the company’s stock after selling 25,239 shares during the quarter. Voya Investment Management LLC’s holdings in Axsome Therapeutics were worth $13,851,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in AXSM. Swiss National Bank grew its position in Axsome Therapeutics by 6.9% in the 2nd quarter. Swiss National Bank now owns 65,200 shares of the company’s stock valued at $6,806,000 after acquiring an additional 4,200 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Axsome Therapeutics by 55.4% during the second quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock valued at $21,257,000 after purchasing an additional 72,609 shares during the period. Los Angeles Capital Management LLC increased its stake in Axsome Therapeutics by 154.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company’s stock worth $462,000 after buying an additional 2,686 shares during the period. Assenagon Asset Management S.A. boosted its position in Axsome Therapeutics by 62.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 294,771 shares of the company’s stock valued at $35,800,000 after buying an additional 113,811 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in shares of Axsome Therapeutics by 33.3% during the first quarter. Affinity Asset Advisors LLC now owns 100,000 shares of the company’s stock valued at $11,663,000 after acquiring an additional 25,000 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Trading Up 1.3%

Shares of NASDAQ:AXSM opened at $154.70 on Tuesday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The firm has a market capitalization of $7.80 billion, a P/E ratio of -33.13 and a beta of 0.47. The business’s 50-day moving average is $141.25 and its 200 day moving average is $122.25. Axsome Therapeutics, Inc. has a 1 year low of $75.56 and a 1 year high of $156.39.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business’s quarterly revenue was up 63.2% compared to the same quarter last year. On average, research analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

AXSM has been the topic of several research reports. HC Wainwright raised their price target on Axsome Therapeutics from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Morgan Stanley increased their target price on Axsome Therapeutics from $194.00 to $196.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Mizuho boosted their price target on Axsome Therapeutics from $200.00 to $202.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company decreased their price objective on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating for the company in a research note on Tuesday, November 4th. Finally, B. Riley assumed coverage on Axsome Therapeutics in a research note on Wednesday, October 1st. They issued a “buy” rating and a $179.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $179.88.

Get Our Latest Stock Analysis on Axsome Therapeutics

Insider Activity at Axsome Therapeutics

In other news, CEO Herriot Tabuteau sold 10,558 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,071,193.22. The trade was a 59.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 289,296 shares of company stock worth $38,882,311 in the last three months. Insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.

Featured Stories

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).